powered by
GameChanger Law Advisors represented Peptris Technologies as they entered into a ground-breaking licensing agreement with Revio Therapeutics, through which Peptris has out-licensed its preclinical-stage asset ๐ฃ๐๐ฃ๐ฅ๐ญ๐ฎ๐ฐ (๐ฅ๐ง๐ฌ๐ฌ๐ญ) for further development in Duchenne Muscular Dystrophy (DMD) โ an extremely rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration, severe disability, and reduced life expectancy.
The licensed asset, PEPR124 (RT001), was discovered by Peptris Technologies using its proprietary AI-driven drug discovery platform, and has shown promising efficacy in preclinical studies for DMD. Peptris Technologies is the ๐๐๐ฅ๐ฆ๐ง Indian company to out-license a drug discovered through an AI-based platform.
This deal reflects the growing impact of AI-driven drug discovery and the potential for strategic global partnerships in accelerating innovative therapies.
The team for this transaction consisted of Senior Partner Samheeta Rao and Associate Dia S..
Source: GameChanger Law Advisorsโ LinkedIn Page
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firmโs name, lawyers involved (including designation) and client represented.